Gene Therapy Clinical Guideline
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline governs UnitedHealthcare coverage and prior authorization requirements for FDA-approved gene and cellular therapies used to treat specified inherited hematologic, neurologic, metabolic, and dermatologic disorders. It affects providers requesting gene therapy for eligible pediatric and adult patients.
The guideline added medical necessity criteria for etuvetidigene autotemcel (Waskyra) for Wiskott-Aldrich syndrome.
The guideline added genotype confirmation requirements for Casgevy and Lyfgenia.
The guideline added medical necessity criteria for marnetegragene autotemcel (Kresladi) for severe leukocyte adhesion deficiency type I.
The indication for elivaldogene autotemcel (Skysona) was updated because of new safety information regarding an increased risk of hematologic malignancy.
Medical necessity criteria were added for etuvetidigene autotemcel (Waskyra) for Wiskott-Aldrich Syndrome.
Genotype confirmation requirements were added for exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia).
Medical necessity criteria were added for marnetegragene autotemcel (Kresladi) for treatment of severe leukocyte adhesion deficiency-type I.
A supplemental FDA approval was added for exagamglogene autotemcel (Casgevy) in patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.